Overview

* Allarity receives FDA Fast Track designation for stenoparib in advanced ovarian cancer

* Company reports median overall survival exceeding 25 months in Phase 2 trial

* Allarity advances DRP platform through new licensing agreement

Outlook

* Allarity expects to launch a Phase 2 trial for small cell lung cancer by year-end 2025

* Company sees potential to broaden stenoparib's reach in multiple cancer types

* Allarity continues enrollment in Phase 2 trial for platinum-resistant ovarian cancer

Result Drivers

* Research and development expenses for the third quarter of 2025 were $1.2 million, compared to $1.0 million for the third quarter of 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$2.81

Income mln

Q3 $2.52

Operatin mln

g

Expenses

Q3 -$2.52

Operatin mln

g Income

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Allarity Therapeutics Inc ( ALLR ) is $9.25, about 87.1% above its November 13 closing price of $1.19

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)